Regulatory functions of TRAIL in hematopoietic progenitors: human umbilical cord blood and murine bone marrow transplantation

[1]  D. Farkas,et al.  Consideration of strategies for hematopoietic cell transplantation. , 2009, Journal of autoimmunity.

[2]  S. de Jong,et al.  TRAIL receptor signalling and modulation: Are we on the right TRAIL? , 2009, Cancer treatment reviews.

[3]  Vishva Dixit,et al.  Death receptor signal transducers: nodes of coordination in immune signaling networks , 2009, Nature Immunology.

[4]  Ralph Weissleder,et al.  Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy , 2009, Proceedings of the National Academy of Sciences.

[5]  Y. Sung,et al.  Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. , 2008, Cancer research.

[6]  P. Secchiero,et al.  Tumor Necrosis Factor‐Related Apoptosis‐Inducing Ligand Promotes Migration of Human Bone Marrow Multipotent Stromal Cells , 2008, Stem cells.

[7]  I. Yaniv,et al.  Reduced-intensity conditioning in children: a reappraisal in 2008 , 2008, Bone Marrow Transplantation.

[8]  V. Boussiotis,et al.  Umbilical cord blood transplantation: basic biology and clinical challenges to immune reconstitution. , 2008, Clinical immunology.

[9]  P. Secchiero,et al.  Tumor necrosis factor-related apoptosis-inducing ligand and the regulation of hematopoiesis , 2008, Current opinion in hematology.

[10]  P. Secchiero,et al.  TRAIL inhibits osteoclastic differentiation by counteracting RANKL‐dependent p27Kip1 accumulation in pre‐osteoclast precursors , 2008, Journal of cellular physiology.

[11]  E. Henson,et al.  The role of TRAIL death receptors in the treatment of hematological malignancies , 2008, Leukemia & lymphoma.

[12]  D. Farkas,et al.  Fas Transduces Dual Apoptotic and Trophic Signals in Hematopoietic Progenitors , 2007, Stem cells.

[13]  I. Yaniv,et al.  Expression of Fas and Fas-ligand in donor hematopoietic stem and progenitor cells is dissociated from the sensitivity to apoptosis. , 2007, Experimental hematology.

[14]  Christoph H Emmerich,et al.  TRAIL signalling: decisions between life and death. , 2007, The international journal of biochemistry & cell biology.

[15]  I. Yaniv,et al.  Fas Ligand Enhances Hematopoietic Cell Engraftment Through Abrogation of Alloimmune Responses and Nonimmunogenic Interactions , 2007, Stem cells.

[16]  M. Manz.  Human-hemato-lymphoid-system mice: opportunities and challenges. , 2007, Immunity.

[17]  L. Gianni,et al.  Targeting TRAIL Agonistic Receptors for Cancer Therapy , 2007, Clinical Cancer Research.

[18]  A. Carbone,et al.  Antitumor activity of human CD34+ cells expressing membrane-bound tumor necrosis factor-related apoptosis-inducing ligand. , 2006, Human gene therapy.

[19]  M. Treiber,et al.  Wogonin sensitizes resistant malignant cells to TNFalpha- and TRAIL-induced apoptosis. , 2006, Blood.

[20]  P. Secchiero,et al.  The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. , 2006, Cytokine & growth factor reviews.

[21]  R. Khosravi‐Far,et al.  Transduction of tumor necrosis factor-related apoptosis-inducing ligand into hematopoietic cells leads to inhibition of syngeneic tumor growth in vivo. , 2006, Cancer research.

[22]  N. Giannakoulas,et al.  A probable role for trail-induced apoptosis in the pathogenesis of marrow failure. Implications from an in vitro model and from marrow of aplastic anemia patients. , 2006, Leukemia research.

[23]  S. Slavin,et al.  Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases. , 2005, Transplant immunology.

[24]  F. Lanza,et al.  Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. , 2005, The American journal of pathology.

[25]  R. Storb,et al.  Low-intensity allogeneic hematopoietic stem cell transplantation for myeloid malignancies: separating graft-versus-leukemia effects from graft-versus-host disease , 2005, Current opinion in hematology.

[26]  G. Zauli,et al.  Emerging non‐apoptotic functions of tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL)/Apo2L , 2004, Journal of cellular physiology.

[27]  U. Testa,et al.  Apoptotic mechanisms in the control of erythropoiesis , 2004, Leukemia.

[28]  P. Secchiero,et al.  TRAIL regulates normal erythroid maturation through an ERK-dependent pathway. , 2004, Blood.

[29]  B. Aggarwal,et al.  Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. , 2003, Biochemical pharmacology.

[30]  B. Aggarwal.  Signalling pathways of the TNF superfamily: a double-edged sword , 2003, Nature Reviews Immunology.

[31]  Kim Ck,et al.  Ex vivo purging of leukemia cells using tumor-necrosis-factor-related apoptosis-inducing ligand in hematopoietic stem cell transplantation. , 2003 .

[32]  G. Cheng,et al.  The signaling adaptors and pathways activated by TNF superfamily. , 2003, Cytokine & growth factor reviews.

[33]  C. Ware.  The TNF superfamily. , 2003, Cytokine & growth factor reviews.

[34]  H. V. van Vlijmen,et al.  Identification of a New Murine Tumor Necrosis Factor Receptor Locus That Contains Two Novel Murine Receptors for Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)* , 2003, The Journal of Biological Chemistry.

[35]  J. Crawford,et al.  T cells require TRAIL for optimal graft-versus-tumor activity , 2002, Nature Medicine.

[36]  P. Secchiero,et al.  Tumor necrosis factor-related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway. , 2002, Blood.

[37]  C. Eaves,et al.  Characterization of Human Hematopoietic Cells with Short‐Lived in Vivo Repopulating Activity , 2001, Annals of the New York Academy of Sciences.

[38]  E. Alnemri,et al.  TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis. , 2000, Blood.

[39]  A. Chinnaiyan,et al.  Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Y. Gazitt.  TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells , 1999, Leukemia.

[41]  S. Srinivasula,et al.  Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1 , 1999, Nature.

[42]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[43]  E. Alnemri,et al.  Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. , 1999, Cancer research.

[44]  C. Maliszewski,et al.  Monocyte-mediated Tumoricidal Activity via the Tumor Necrosis Factor–related Cytokine, TRAIL , 1999, The Journal of experimental medicine.

[45]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[46]  D. Harris,et al.  Analysis of the alloreactive capacity of human umbilical cord blood: implications for graft-versus-host disease. , 1994, Bone marrow transplantation.

[47]  R. Greil,et al.  Tuning the rheostat of the myelopoietic system via Fas and TRAIL. , 2003, Critical reviews in immunology.

[48]  J. Jelinek,et al.  TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors , 2002, Leukemia.